AbbVie Inc. has released preliminary financial results for the third quarter of 2024, including the impact of acquired IPR&D and milestones expense. The company reported an expense of $82 million on a pre-tax basis, which is expected to negatively affect both GAAP and non-GAAP diluted earnings per share by $0.04. AbbVie's third quarter results have not been finalized and are subject to financial statement closing procedures. The company's full-year 2024 adjusted diluted earnings per share guidance, including the third quarter expense, is projected to be between $10.67 and $10.87. The third quarter adjusted diluted earnings per share guidance is estimated to be between $2.88 and $2.92, reflecting the incurred expense. AbbVie has previously announced that its adjusted diluted earnings per share guidance for 2024 would exclude the impact of any acquired IPR&D and milestones expense beyond the second quarter. The company cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied.

AbbVie Inc. has released preliminary financial results for the third quarter of 2024, including the impact of acquired IPR&D and milestones expense. The company reported an expense of $82 million on a pre-tax basis, which is expected to negatively affect both GAAP and non-GAAP diluted earnings per share by $0.04. AbbVie's third quarter results have not been finalized and are subject to financial statement closing procedures. The company's full-year 2024 adjusted diluted earnings per share guidance, including the third quarter expense, is projected to be between $10.67 and $10.87. The third quarter adjusted diluted earnings per share guidance is estimated to be between $2.88 and $2.92, reflecting the incurred expense. AbbVie has previously announced that its adjusted diluted earnings per share guidance for 2024 would exclude the impact of any acquired IPR&D and milestones expense beyond the second quarter. The company cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied.